Le Lézard
Classified in: Science and technology
Subject: Contract/Agreement

CACI Awarded a Multiple-Award U.S. Air Force Contract to Develop Advanced Battle Management System


CACI International Inc (NYSE:CACI) announced today that it has been awarded an indefinite-delivery/indefinite-quantity contract by the U.S. Air Force Life Cycle Management Center/Chief Architect Integration Office for the maturation, demonstration and proliferation of capability across platforms and domains, leveraging open systems design, modern software and algorithm development in order to enable Joint All Domain Command and Control (JADC2).

This contract is part of a multiple award multi-level security effort to provide development and operation of systems as a unified force across all domains (air, land, sea, space, cyber, and electromagnetic spectrum) in an open architecture family of systems that enables capabilities via multiple integrated platforms.

John Mengucci, CACI President and Chief Executive Officer, said, "CACI stands ready to provide critical mission expertise and technology to the U.S. Air Force's JADC2 effort, to help U.S. forces integrate operations across all domains and against any adversary."

CACI Executive Chairman and Chairman of the Board Dr. J.P. (Jack) London, said, "CACI is prepared to provide the integrated and multidomain capabilities the U.S. military requires, as our country faces a more complex array of threats than ever before."

CACI's 23,000 talented employees are vigilant in providing the unique expertise and distinctive technology that address our customers' greatest enterprise and mission challenges. Our culture of good character, innovation, and excellence drives our success and earns us recognition as a Fortune World's Most Admired Company. As a member of the Fortune 1000 Largest Companies, the Russell 1000 Index, and the S&P MidCap 400 Index, we consistently deliver strong shareholder value. Visit us at www.caci.com.

There are statements made herein which do not address historical facts, and therefore could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The factors that could cause actual results to differ materially from those anticipated include, but are not limited to, the risk factors set forth in CACI's Annual Report on Form 10-K for the fiscal year ended June 30, 2019, and other such filings that CACI makes with the Securities and Exchange Commission from time to time. Any forward-looking statements should not be unduly relied upon and only speak as of the date hereof.

CACI-Contract Award


These press releases may also interest you

at 10:15
It's nearly Small Business Week and T-Mobile is going big for small business customers with deals starting April 25! T-Mobile is launching Business Unlimited Edge and new small business customers that add at least 10 or more lines can get up to a...

at 10:15
Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Kwan-Ho "Alex" Chung, Ph.D. has joined the firm's Intellectual Property practice group and Life Sciences industry team in Washington, D.C. Chung was most recently a partner at...

at 10:14
Public health researchers have a new, powerful tool from data and AI provider SAS to analyze the National Institutes of Health's All of Us Research Program's large and diverse data set. The NIH has added SAS Analytics Pro on SAS® Viya® to the All of...

at 10:10
HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical...

at 10:10
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of two abstracts for poster presentation...

at 10:10
Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological diseases, announced today that two abstracts featuring the latest data on sunvozertinib in non-small...



News published on and distributed by: